SciSparc Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SPRC | 18H0.F | CANF | SILO | ARTL | EDVA | |
|---|---|---|---|---|---|---|
| Market cap | 297.81K | 5.11M | 5.06M | 2.93M | 1.24M | 2.11M |
| P/E (TTM) | 0.0 | — | — | — | — | — |
| Forward P/E | — | — | -1.8 | -1.9 | -2.6 | — |
| Price/book | 0.1 | -1.1 | 0.7 | 0.3 | 0.2 | 0.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −97.79% | −38.46% | −80.71% | −83.17% | −95.42% | −96.76% |
| Today | −14.48% | −23.81% | +3.02% | +3.91% | −5.42% | +3.23% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SPRC news ›SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
TEL AVIV, Israel, October 26th, 2026, FinanceWire SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance…
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
Oct 26, 2026, 08:30 ET Based on the anchor- and distribution-based analyses, researchers established a 6-point increase in EQ-VAS score as the minimum clinically meaningful within-patient change threshold. The 6-point threshold was also…
NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
TORONTO, ONTARIO - October 22, 2026 (NEWMEDIAWIRE) - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced further progress in its U.S.…
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as…
Why Is SciSparc Stock Gaining Thursday?
SciSparc Ltd. SPRC stock jumped more than 18% Thursday after the company announced a strategic shift toward agentic artificial intelligence technologies, with a focus on cybersecurity and financial applications. The move marks a potential…
SciSparc offers $2.02M debt conversion at $1.50
The proposed conversion would exchange $2,023,039.21 of principal and accrued interest for shares, with no cash proceeds to SciSparc. Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of…
SciSparc plans AI shift into cybersecurity and finance
The company says its AI-market evaluation may not lead to a transaction, commercial agreement or revenue-generating activity. The 6-K incorporates its October 15 press release by reference into SciSparc’s listed F-3 and S-8 registration…
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
Profusa Receives ISO 13485:2016 Certificate from GMED SciSparc (Nasdaq: SPRC) announced plans to shift its strategic focus toward agentic artificial intelligence technologies, including cybersecurity and finance applications. These systems…
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com5
- stocktitan.net5
- ibtimes.com1
- markets.financialcontent.com1
- newmediawire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.